CytoDyn Inc CYDY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.21
- Day Range
- $0.20–0.21
- 52-Week Range
- $0.18–0.40
- Bid/Ask
- $0.19 / $0.22
- Shares Outstanding
- 1.47B
- Market Cap
- $271.84M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 12.90
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CytoDyn Inc is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of its product candidate, leronlimab, which is being studied for its potential in solid-tumor oncology. Leronlimab targets CCR5, a receptor increasingly recognized for its role in tumor progression, metastasis and immune regulation, providing the company with the opportunity to explore a potentially differentiated therapeutic approach across multiple solid tumor indications. It operates as a single reporting segment, focused on the clinical development of leronlimab.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 14
- Website
- https://www.cytodyn.com
Valuation
|
Metric
|
CYDY
|
|---|---|
Price/Earnings (Normalized) | 12.90 |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CYDY
Financial Strength
|
Metric
|
CYDY
|
|---|---|
Quick Ratio | 0.22 |
Current Ratio | 0.26 |
Interest Coverage | −16.26 |
Quick Ratio
CYDY
Profitability
|
Metric
|
CYDY
|
|---|---|
Return on Assets (Normalized) | −176.34% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
CYDY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|rVW@y< | LOCK|L#Qb | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|tQ&MsjM | LOCK|P^>^p | $76B | |||
| Moderna Inc
MRNA
| LOCK|^sfb<f | LOCK|&$F | $75B | |||
| argenx SE ADR
ARGX
| LOCK|^PZym> | LOCK|sy | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Gdx&?L | LOCK|q% | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|VSzNYB | LOCK|<%@Hp | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|q@MH$&P | LOCK|$L^q | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|<bHrj^h | LOCK|G&k | $24B | |||
| Incyte Corp
INCY
| LOCK|Tg<$j%L | LOCK|@# | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@Pyv&@ | LOCK|!? | $15B |
United States